Exkon said:
No appetite suppressant effect?
Thats my main reason for using it as I have a hard time controling my appetite when I'm out of my bulker mode
Its not an appetite suppresant. It allows your body to metabolize glocose better. Kind of like ALA
In December 1994, the U.S. Food and Drug Administration (FDA) approved the use of metformin for the treatment of Type 2 diabetes. Metformin was approved for use either alone or with sulfonylureas, a commonly used group of diabetes medicines. Metformin's brand name is Glucophage.
Metformin is in the group of diabetes medicines called biguanides. Metformin lowers blood sugar by keeping the liver from making too much sugar. The medicine does not increase how much insulin the pancreas makes. Metformin also helps lower the fatty blood components—triglycerides and cholesterol—that are often high in people with Type 2 diabetes. Metformin also has been shown to decrease the appetite and help people lose a few pounds when they starting taking the medicine. Another benefit of metformin is that it does not cause low blood sugar (hypoglycemia) when it is used as the only diabetes medicine.
Metformin can cause side effects such as nausea, stomach pain, bloating, and diarrhea. These side effects usually go away soon after the metformin is started and occur less often if metformin is taken with food. Another possible problem with metformin is a rare but serious condition called lactic acidosis, when your tissues do not get enough oxygen to survive. To avoid this problem, metformin should not be given to people with kidney or liver disease, severe heart failure, or a history of alcohol abuse.
Information about metformin is contained in the National Diabetes Information Clearinghouse booklet "Medicines for People with Diabetes." To learn more about metformin, ask your health care provider.
The U.S. Government does not endorse or favor any specific commercial product or company. Trade, proprietary, or company names appearing in this summary are used only because they are considered essential in the context of the information provided herein.
--------------------------------------------------------------------------------
Additional Information on Metformin
The National Diabetes Information Clearinghouse collects resource information on diabetes for Combined Health Information Database (CHID). CHID is a database produced by health-related agencies of the Federal Government. This database provides titles, abstracts, and availability information for health information and health education resources.
To provide you with the most up-to-date resources, information specialists at the clearinghouse created an automatic search of CHID. To obtain this information you may view the results of the automatic search on Metformin.
Or, if you wish to perform your own search of the database, you may access the CHID Online web site and search CHID yourself.
--------------------------------------------------------------------------------
National Diabetes Information Clearinghouse
1 Information Way
Bethesda, MD 20892-3560
E-mail: National Diabetes Information Clearinghouse
The National Diabetes Information Clearinghouse (NDIC) is a service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The NIDDK is part of the National Institutes of Health under the U.S. Department of Health and Human Services. Established in 1978, the clearinghouse provides information about diabetes to people with diabetes and their families, health care professionals, and the public. NDIC answers inquiries; develops, reviews, and distributes publications; and works closely with professional and patient organizations and Government agencies to coordinate resources about diabetes.
Publications produced by the clearinghouse are reviewed carefully for scientific accuracy, content, and readability.
This e-text is not copyrighted. The clearinghouse encourages users of this e-pub to duplicate and distribute as many copies as desired.
--------------------------------------------------------------------------------
e-text posted: 17 March 1998